These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34138776)

  • 1. Anti-Interleukin 23-Based Therapies May Shift Cutaneous Immune Responses: A Case of New-Onset Contact Dermatitis to Carbamates After Guselkumab for Psoriasis.
    Liakos W; Toussi A; Le ST; Ma C; Merleev A; Marusina AI; Luxardi G; Konia TH; Sood A; Wu PA; Maverakis E
    Dermatitis; 2021 Nov-Dec 01; 32(6):e113-e115. PubMed ID: 34138776
    [No Abstract]   [Full Text] [Related]  

  • 2. Nummular dermatitis on guselkumab for palmoplantar psoriasis.
    Truong A; Le S; Kiuru M; Maverakis E
    Dermatol Ther; 2019 Jul; 32(4):e12954. PubMed ID: 31070862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 4. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 6. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Guselkumab].
    Montaudié H;
    Ann Dermatol Venereol; 2019; 146(6-7):515-519. PubMed ID: 31200928
    [No Abstract]   [Full Text] [Related]  

  • 8. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
    JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction.
    Hosokawa Y; Hamada T; Ashida H; Ikeda M
    J Dermatol; 2019 Aug; 46(8):e302-e303. PubMed ID: 30861165
    [No Abstract]   [Full Text] [Related]  

  • 12. A safety evaluation of guselkumab for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
    Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C.
    Warren RB; Al-Rifai A
    Br J Dermatol; 2013 Mar; 168(3):461-2. PubMed ID: 23445306
    [No Abstract]   [Full Text] [Related]  

  • 18. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
    Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
    J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumour necrosis factor-α treatment and weight gain in psoriasis: the 'pudgy blanching' conundrum.
    Puig L
    Br J Dermatol; 2013 May; 168(5):923-4. PubMed ID: 23614557
    [No Abstract]   [Full Text] [Related]  

  • 20. Pleural Fluid Eosinophilia: A Possible Adverse Event of Interleukin-17 Inhibition.
    Hayashi W; Osada SI; Toyoshima A; Yamada K; Sudo K; Nakayama K; Manabe M
    Acta Derm Venereol; 2019 Nov; 99(12):1174-1175. PubMed ID: 31502653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.